Serum Uric Acid and Risk for Acute Kidney Injury Following Contrast: An Evaluation of Epidemiology, Clinical Trials, and Potential Mechanisms

Angiology

Volumn 68, Issue 2, 2017, Pages 132-144

  Kanbay, Mehmet ^a   Solak, Yalcin ^b   Afsar, Baris ^c   Nistor, Ionut ^d,e   Aslan, Gamze ^a   Çaǧlayan, Ozlem Hilal ^a   Aykanat, Asli ^a   Donciu, Mihaela Dora ^d   Lanaspa, Miguel A ^f   Ejaz, Ahsan A ^g   Johnson, Richard J ^f   Covic, Adrian ^d  

^a KOÇ UNIVERSITY   (Turkey)

^b Sakarya Training and Research Hospital ^*  (Turkey)

^c Konya Numune State Hospital   (Turkey)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

Author keywords

acute kidney injury; allopurinol; contrast nephropathy; uric acid

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; CREATININE; URIC ACID; BIOLOGICAL MARKER; CONTRAST MEDIUM;

ACUTE KIDNEY FAILURE; ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL (TOPIC); CONTRAST INDUCED NEPHROPATHY; GENETIC HETEROGENEITY; GLOMERULUS FILTRATION RATE; HUMAN; HYDRATION; HYPERURICEMIA; HYPERURICOSURIA; KIDNEY FUNCTION; META ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; BLOOD; CHEMICALLY INDUCED;

ACUTE KIDNEY INJURY; BIOMARKERS; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; HUMANS; RISK FACTORS; URIC ACID;

EID: 85007306056     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319716644395     Document Type: Article

References (43)

1. Keaney JJ, Hannon CM, Murray PT,. Contrast-induced acute kidney injury: how much contrast is safe? Nephrol Dial Transpl. 2013; 28 (6): 1376-1383.
2. Morcos SK, Thomsen HS, Webb JA,. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999; 9 (8): 1602-1613.
3. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP,. Contrast-Induced nephropathy: an "all or none" phenomenon? Angiology. 2015; 66 (6): 508-513.
4. Nicola R, Shaqdan KW, Aran K, Mansouri M, Singh A, Abujudeh HH,. Contrast-induced nephropathy: identifying the risks, choosing the right agent, and reviewing effective prevention and management methods. Curr Probl Diagn Radiol. 2015; 44 (6): 501-504.
5. Chen SP, Cheung W, Heng CK, Jordan SC, Yap HK,. Childhood nephrotic syndrome in relapse is associated with down-regulation of monocyte CD14 expression and lipopolysaccharide-induced tumour necrosis factor-alpha production. Clin Exp Immunol. 2003; 134 (1): 111-119.
6. Tsimberidou AM, Keating MJ,. Hyperuricemic syndromes in cancer patients. Contrib Nephrol. 2005; 147: 47-60.
7. Ejaz AA, Beaver TM, Shimada M, et al. Uric acid: a novel risk factor for acute kidney injury in high-risk cardiac surgery patients? Am J Nephrol. 2009; 30 (5): 425-429.
8. Ejaz AA, Kambhampati G, Ejaz NI, et al. Post-operative serum uric acid and acute kidney injury. J Nephrol. 2012; 25 (4): 497-505.
9. Lapsia V, Johnson RJ, Dass B, et al. Elevated uric acid increases the risk for acute kidney injury. Am J Med. 2012; 125 (3):302. e309-e317.
10. Roncal CA, Mu W, Croker B, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol. 2007; 292 (1): F116-F122.
11. Ejaz AA, Dass B, Lingegowda V, et al. Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery. Int Urol Nephrol. 2013; 45 (2): 449-458.
12. Barbieri L, Verdoia M, Schaffer A, et al. Uric acid levels and the risk of contrast induced nephropathy in patients undergoing coronary angiography or PCI. Nutr Metab Cardiovasc Dis. 2015; 25 (2): 181-186.
13. Liu Y, Tan N, Chen J, et al. The relationship between hyperuricemia and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with relatively normal serum creatinine. Clinics (Sao Paulo). 2013; 68 (1): 19-25.
14. Toprak O, Cirit M, Esi E, Postaci N, Yesil M, Bayata S,. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv. 2006; 67 (2): 227-235.
15. Kowalczyk J, Francuz P, Swoboda R, et al. Prognostic significance of hyperuricemia in patients with different types of renal dysfunction and acute myocardial infarction treated with percutaneous coronary intervention. Nephron Clin Pract. 2010; 116 (2): c114-c122.
16. Toprak O, Cirit M, Yesil M, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant. 2007; 22 (3): 819-826.
17. Elbasan Z, Sahin DY, Gur M, et al. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology. 2014; 65 (1): 37-42.
18. Saritemur M, Turkeli M, Kalkan K, Tanboga IH, Aksakal E,. Relation of uric acid and contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention in the ED. Am J Emerg Med. 2014; 32 (2): 119-123.
19. Park SH, Shin WY, Lee EY, et al. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ J. 2011; 75 (3): 692-697.
20. Okino S, Fukuzawa S, Inagaki M, et al. Hyperuricemia as a risk factor for progressive renal insufficiency after coronary intervention in patients with chronic kidney disease. Cardiovascr Intervention Therap. 2010; 25 (2): 105-111.
21. Karabulut A, Sahin I, Ilker Avci I, et al. Impact of serum alkaline phosphatase level on the pathophysiologic mechanism of contrast-induced nephropathy. Kardiol Pol. 2014; 72 (10): 977-982.
22. Erol T, Tekin A, Katircibasi MT, et al. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol. 2013; 167 (4): 1396-1399.
23. Kumar A, Bhawani G, Kumari N, Murthy KS, Lalwani V, Raju Ch N,. Comparative study of renal protective effects of allopurinol and N -acetyl-cysteine on contrast induced nephropathy in patients undergoing cardiac catheterization. J Clin Diagn Res. 2014; 8 (12): HC03-HC07.
24. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21 (11): 1539-1558.
25. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7 (3): 177-188.
26. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315 (7109): 629-634.
27. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50 (4): 1088-1101.
28. Mendi MA, Afsar B, Oksuz F, et al. Uric acid is a useful tool to predict contrast-induced nephropathy [published online March 22, 2016]. Angiology. 2016. doi: https://doi.org/10.1177/0003319716639187
29. Guo W, Liu Y, Chen JY, et al. Hyperuricemia is an independent predictor of contrast-induced acute kidney injury and mortality in patients undergoing percutaneous coronary intervention. Angiology. 2015; 66 (8): 721-726.
30. Kelley WN,. Uricosuria and x-ray contrast agents. N Engl J Med. 1971; 284 (17): 975-976.
31. Postlethwaite AE, Kelley WN,. Uricosuric effect of radiocontrast agents. A study in man of four commonly used preparations. Ann Intern Med. 1971; 74 (6): 845-852.
32. Schepers MS, van Ballegooijen ES, Bangma CH, Verkoelen CF,. Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int. 2005; 68 (4): 1543-1553.
33. Ryu ES, Kim MJ, Shin HS, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013; 304 (5): F471-F480.
34. Han HJ, Lim MJ, Lee YJ, Lee JH, Yang IS, Taub M,. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB. Am J Physiol Renal Physiol. 2007; 292 (1): F373-F381.
35. Verzola D, Ratto E, Villaggio B, et al. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PloS One. 2014; 9 (12): e115210.
36. Zhou Y, Fang L, Jiang L, et al. Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway. PloS one. 2012; 7 (6): e39738.
37. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005; 67 (5): 1739-1742.
38. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011; 6 (8): 1887-1894.
39. Kanbay M, Siriopol D, Nistor I, et al. Effects of allopurinol on endothelial dysfunction: a meta-analysis. Am J Nephrol. 2014; 39 (4): 348-356.
40. Kang DH, Park SK, Lee IK, Johnson RJ,. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005; 16 (12): 3553-3562.
41. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003; 41 (6): 1287-1293.
42. Cirillo P, Gersch MS, Mu W, et al. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol. 2009; 20 (3): 545-553.
43. Roncal-Jimenez CA, Garcia-Trabanino R, Barregard L, et al. Heat stress nephropathy from exercise-induced uric acid crystalluria: a perspective on Mesoamerican nephropathy. Am J Kidney Dis. 2016; 67 (1): 20-30.